Skip to content

Sponsored

Faith at Work: Economic Flourishing and Securing Our Future

TRENDING:
Donald Trump
Advertisement

This photo provided by Genentech shows the company's drug Ocrevus. Late Tuesday, March 28, 2017, the Food and Drug Administration approved Ocrevus, the first drug for an aggressive kind of multiple sclerosis that steadily reduces coordination and the ability to walk. While there are more than a dozen treatments for the most common form of MS, there's been nothing specifically for people with the type called primary progressive MS. That type of MS is relatively rare, affecting about 50,000 Americans. Ocrevus was also approved for relapsing forms of MS, which progress more slowly.(Genentech via AP)

This photo provided by Genentech shows the company's drug Ocrevus. Late Tuesday, March 28, 2017, the Food and Drug Administration approved Ocrevus, the first drug for an aggressive kind of multiple sclerosis that steadily reduces coordination and the ability to walk. While there are more than a dozen treatments for the most common form of MS, there's been nothing specifically for people with the type called primary progressive MS. That type of MS is relatively rare, affecting about 50,000 Americans. Ocrevus was also approved for relapsing forms of MS, which progress more slowly.(Genentech via AP)

Featured Photo Galleries

01-Army parade.png

Military parade celebrates Army’s 250th

Cheers and chants rang out Saturday from a crowd of thousands as soldiers manned modern and historic tanks and aircraft for the Army’s 250th anniversary celebration in the District.

20250330 Sabatini-Caps-Sabres 001.jpg

Ovi scores goal 890, Caps lose to Sabres 8-5

Alexander Ovechkin scored goal number 890, but the Washington Capitals fell short, losing to the visiting Buffalo Sabres Sunday afternoon 8-5 at Capital One Arena in Washington D.C., March 30, 2025 (Photos for the Washington Times.)